These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37920237)

  • 1. Sustained long-term disease correction in a murine model of MPSII following stem cell gene therapy.
    Ellison S; Liao A; Gleitz HFE; Parker H; Booth L; Robinson J; Wood S; Taylor J; Holley R; Bigger BW
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101127. PubMed ID: 37920237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms.
    Gleitz HF; Liao AY; Cook JR; Rowlston SF; Forte GM; D'Souza Z; O'Leary C; Holley RJ; Bigger BW
    EMBO Mol Med; 2018 Jul; 10(7):. PubMed ID: 29884617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion of Rabies Virus Glycoprotein or gh625 to Iduronate-2-Sulfatase for the Treatment of Mucopolysaccharidosis Type II.
    Wood SR; Chaudrhy A; Ellison S; Searle R; Burgod C; Tehseen G; Forte G; O'Leary C; Gleitz H; Liao A; Cook J; Holley R; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):232-242. PubMed ID: 37212263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of the Effectiveness of Early Versus Late Stem Cell Gene Therapy in Mucopolysaccharidosis II for Treating Central Versus Peripheral Disease.
    Mandolfo O; Liao A; Singh E; O'leary C; Holley RJ; Bigger BW
    Hum Gene Ther; 2024 Apr; 35(7-8):243-255. PubMed ID: 37427450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and validation of a GMP stem cell manufacturing protocol for MPSII hematopoietic stem cell gene therapy.
    Ellison S; Buckland K; Learmonth Y; Day V; Kalra S; Howe L; Roman-Rodriguez FJ; Bonafont J; Booth L; Holley R; Smythe J; Jones S; Thrasher A; Booth C; Bigger BW
    Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101271. PubMed ID: 38946936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery.
    Cardone M; Polito VA; Pepe S; Mann L; D'Azzo A; Auricchio A; Ballabio A; Cosma MP
    Hum Mol Genet; 2006 Apr; 15(7):1225-36. PubMed ID: 16505002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome).
    Motas S; Haurigot V; Garcia M; Marcó S; Ribera A; Roca C; Sánchez X; Sánchez V; Molas M; Bertolin J; Maggioni L; León X; Ruberte J; Bosch F
    JCI Insight; 2016 Jun; 1(9):e86696. PubMed ID: 27699273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy.
    Polito VA; Abbondante S; Polishchuk RS; Nusco E; Salvia R; Cosma MP
    Hum Mol Genet; 2010 Dec; 19(24):4871-85. PubMed ID: 20876612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDS crossing of the blood-brain barrier corrects CNS defects in MPSII mice.
    Polito VA; Cosma MP
    Am J Hum Genet; 2009 Aug; 85(2):296-301. PubMed ID: 19679226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
    Gusarova VD; Smolov MA; Lyagoskin IV; Degterev MB; Rechetnik EV; Rodionov AV; Pantyushenko MS; Shukurov RR
    BioDrugs; 2023 May; 37(3):375-395. PubMed ID: 37014547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles.
    Rigon L; Salvalaio M; Pederzoli F; Legnini E; Duskey JT; D'Avanzo F; De Filippis C; Ruozi B; Marin O; Vandelli MA; Ottonelli I; Scarpa M; Tosi G; Tomanin R
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31022913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II.
    Rybová J; Ledvinová J; Sikora J; Kuchař L; Dobrovolný R
    J Inherit Metab Dis; 2018 Mar; 41(2):221-229. PubMed ID: 29168031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage.
    Catalano F; Vlaar EC; Dammou Z; Katsavelis D; Huizer TF; Zundo G; Hoogeveen-Westerveld M; Oussoren E; van den Hout HJMP; Schaaf G; Pike-Overzet K; Staal FJT; van der Ploeg AT; Pijnappel WWMP
    Hum Gene Ther; 2024 Apr; 35(7-8):256-268. PubMed ID: 38085235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glial degeneration with oxidative damage drives neuronal demise in MPSII disease.
    Zalfa C; Verpelli C; D'Avanzo F; Tomanin R; Vicidomini C; Cajola L; Manara R; Sala C; Scarpa M; Vescovi AL; De Filippis L
    Cell Death Dis; 2016 Aug; 7(8):e2331. PubMed ID: 27512952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of
    Smith MC; Belur LR; Karlen AD; Erlanson O; Podetz-Pedersen KM; McKenzie J; Detellis J; Gagnidze K; Parsons G; Robinson N; Labarre S; Shah S; Furcich J; Lund TC; Tsai HC; McIvor RS; Bonner M
    Hum Gene Ther; 2022 Dec; 33(23-24):1279-1292. PubMed ID: 36226412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tagged IDS causes efficient and engraftment-independent prevention of brain pathology during lentiviral gene therapy for Mucopolysaccharidosis type II.
    Catalano F; Vlaar EC; Katsavelis D; Dammou Z; Huizer TF; van den Bosch JC; Hoogeveen-Westerveld M; van den Hout HJMP; Oussoren E; Ruijter GJG; Schaaf G; Pike-Overzet K; Staal FJT; van der Ploeg AT; Pijnappel WWMP
    Mol Ther Methods Clin Dev; 2023 Dec; 31():101149. PubMed ID: 38033460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF signaling deregulation is associated with early developmental skeletal defects in animal models for mucopolysaccharidosis type II (MPSII).
    Bellesso S; Salvalaio M; Lualdi S; Tognon E; Costa R; Braghetta P; Giraudo C; Stramare R; Rigon L; Filocamo M; Tomanin R; Moro E
    Hum Mol Genet; 2018 Jul; 27(13):2262-2275. PubMed ID: 29648648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System-Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer.
    Laoharawee K; Podetz-Pedersen KM; Nguyen TT; Evenstar LB; Kitto KF; Nan Z; Fairbanks CA; Low WC; Kozarsky KF; McIvor RS
    Hum Gene Ther; 2017 Aug; 28(8):626-638. PubMed ID: 28478695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II.
    Das S; Rruga F; Montepeloso A; Dimartino A; Spadini S; Corre G; Patel J; Cavalca E; Ferro F; Gatti A; Milazzo R; Galy A; Politi LS; Rizzardi GP; Vallanti G; Poletti V; Biffi A
    Mol Ther; 2024 Mar; 32(3):619-636. PubMed ID: 38310355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.